Monte Rosa Therapeutics, Inc. (GLUE) is a publicly traded company in the Unknown sector. Across all available filings, 18 corporate insiders have executed 66 transactions totaling $287.6M, demonstrating a bullish sentiment with $265.9M in net insider flow. The most recent transaction on Sep 20, 2024 involved a sale of 1,132,566 shares valued at $7.4M.
No significant insider buying has been recorded for GLUE in the recent period.
No significant insider selling has been recorded for GLUE in the recent period.
Based on recent SEC filings, insider sentiment for GLUE is bullish with an Insider Alignment Score of 96/100 and a net flow of $265.9M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Monte Rosa Therapeutics, Inc. (GLUE) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 18 insiders are actively trading GLUE stock, having executed 66 transactions in the past 90 days. The most active insider is Partners 17, L.p. Nea (Executive), who has made 4 transactions totaling $19.9M.
Get notified when executives and directors at GLUE file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Sep 20, 2024 | Capital Vi, L.p. Versant Venture | Executive | Sale | 1,132,566 | $6.53 | $7.4M | Large |
| Sep 13, 2024 | VI Gp, L.p. Versant Ventures | Executive | Sale | 9,269 | $6.16 | $57.1K | |
| Sep 12, 2024 | VI Gp, L.p. Versant Ventures | Executive | Sale | 16,047 | $6.00 | $96.3K | |
| Sep 11, 2024 | VI Gp, L.p. Versant Ventures | Executive | Sale | 541,897 | $6.00 | $3.3M | Large |
| Jul 5, 2024 | Dunn Edmund | Executive | Sale | 1,610 | $3.83 | $6.2K | |
| Jun 3, 2024 | Dunn Edmund | Executive | Sale | 1,207 | $4.04 | $4.9K | |
| Jun 28, 2021 | Management, Lp Cormorant Asset | Executive | Purchase | 600,000 | $19.00 | $11.4M | Large |
| Jun 28, 2021 | Management, Lp Cormorant Asset | Executive | Conversion | 2,602,200 | $N/A | $0 | |
| Jun 28, 2021 | VI Gp, L.p. Versant Ventures | Executive | Purchase | 157,895 | $19.00 | $3.0M | Large |
| Jun 28, 2021 | VI Gp, L.p. Versant Ventures | Executive | Conversion | 6,515,869 | $N/A | $0 | |
| Jun 28, 2021 | VI Gp, L.p. Versant Ventures | Executive | Conversion | 1,940,043 | $N/A | $0 | |
| Jun 28, 2021 | J. Bolzon Bradley Phd | Executive | Conversion | 1,940,043 | $N/A | $0 | |
| Jun 28, 2021 | J. Bolzon Bradley Phd | Executive | Purchase | 157,895 | $19.00 | $3.0M | Large |
| Jun 28, 2021 | J. Bolzon Bradley Phd | Executive | Conversion | 6,515,869 | $N/A | $0 | |
| Jun 28, 2021 | 17, L.p. Nea Partners | Executive | Purchase | 1,050,000 | $19.00 | $19.9M | Large |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 16 | $276.8M | 96.2% |
Sale(S) | 6 | $10.8M | 3.8% |
Conversion(C) | 44 | $0 | 0.0% |
Insiders at Monte Rosa Therapeutics, Inc. are accumulating shares at an accelerated pace. With 18 insiders making 66 transactions totaling $276.8M in purchases versus $10.8M in sales, the net buying activity of $265.9M signals strong executive confidence. Partners 17, L.p. Nea (Executive) leads the buying activity with $19.9M in transactions across all time.